Skip to content

MiniMed Group MMED International — Net Sales

Similar metrics at other companies

Abbott logo
ABTInternational — Net Sales
$6.89B+11.3%
Baxter International logo
BAXInternational — Net Sales
$1.27B+11.5%
Globus Medical logo
GMEDInternational — Net Sales
$154.97M+35.6%
Medtronic logo
MDTInternational — Net Sales
$4.94B+12.8%
Stryker logo
SYKInternational — Net Sales
$1.54B+8.3%
Medline, Inc.
 logo
MDLNInternational — Net Sales
$495M+10.0%

Other financials

Income statement

See full
Revenue$790.0M+15.0%
Gross profit$362.0M-8.4%
Operating income-$100.0M-576%
Net income-$119.0M-1,090%
EPS (diluted)-$0.47-1,075%

Balance sheet

See full
Cash & equivalents$10.0M0.0%
Total debt$61.0M
Total equity$3.5B-0.7%
Total assets$4.3B

Cash flow

See full
Operating cash flow-$27.0M-147%
CapEx$167.0M+22.8%
Free cash flow-$194.0M-146%

Valuation

See full
Market cap$4.15B
Enterprise value$4.2B

Returns & leverage

See full
Return on equity-4.3%
Debt / equity
Current ratio1.6×

Where this comes from

Reported directly by MiniMed Group in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: MiniMed Group ’s 10-Q, filed April 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiniMed Group 's international — net sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MiniMed Group 's international — net sales?
MiniMed Group (MMED) reported international — net sales of $548M in Q1 2026.
What does international — net sales mean?
This metric represents the total revenue generated from the sale of medical devices and diabetes management solutions in geographic regions outside of the company's primary domestic market. It reflects the company's global market penetration, international demand for its insulin pump and glucose monitoring technologies, and the effectiveness of its overseas distribution networks. Tracking this figure helps investors assess the company's geographic diversification and its ability to capture growth opportunities in non-domestic healthcare markets.